Specialised diagnostic kits manufacturer Corgenix has signed an agreement with Eli Lilly and Company, a US-based pharmaceutical company, to develop diagnostic technology in support of the Lilly oncology pipeline programme.
Focusing on a variety of difficult-to-treat cancers, the Lilly oncology programme has more than 20 molecules in early and late-stage development.
As per the terms of the agreement, both the companies will jointly advance the proprietary diagnostic technology, originally developed by Lilly.
The financial details of the collaboration agreement have not been divulged.
Corgenix president and CEO Douglass Simpson said this relationship strengthens the company's programme of strategic alliances in key areas of laboratory and research medicine.
"The Lilly collaboration in particular opens a new door for Corgenix as we continue to explore this technology in global clinical research as potential new technology to meet the needs of oncology clinicians worldwide," Simpson added.
The partnership with Lilly is a part of Corgenix' expansion of its contract services business unit for product development, technology application and production for the healthcare and biotechnology industries.
Corgenix manufactures specialised diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the non-blood-based test for aspirin effect.
Image: Eli Lilly Headquarters. Photo: Courtesy of Guanaco152003.